Praxis reports positive seizure reduction results from vormatrigine trial
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- US futures fall on tech selloff as concerns about hawkish Fed, AI spending mount
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Praxis Precision Medicines Announces Positive, Best-in-Disease Topline Results in Patients with Focal Onset Seizures from the RADIANT Study of Vormatrigine
August 4, 2025 8:00 AM EDTDosing with vormatrigine over 8 weeks led to 56.3% median reduction in seizure frequency
Approximately 22% of patients reached 100% reduction in seizure frequency in the last 28 days on treatment
Rapid and sustained response, with over 54% of patients achieving 50% response in the first week
Vormatrigine was generally well tolerated and continues to demonstrate favorable safety profile
BOSTON, Aug. 04, 2025 (GLOBE NEWSWIRE) --... More
